Innovation Holdings

Innovation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a new class of small molecule therapies based on its proprietary defensin mimetic platform. The company's lead drug candidate, Brilacidin, is a first-in-class immunomodulatory agent with potent anti-inflammatory and antimicrobial properties, currently being evaluated for indications such as oral mucositis, inflammatory bowel disease, and COVID-19. Additionally, the company is advancing Kevetrin, a small molecule p53 activator designed to treat various solid tumors by restoring the body's natural tumor-suppression mechanisms. Innovation Pharmaceuticals aims to address significant unmet medical needs across oncology, inflammatory diseases, and infectious diseases through its innovative chemical scaffolds.